This review examines radiotheranostics in personalized medicine, combining diagnostic imaging and targeted radioimmunotherapy for effective cancer treatment. It highlights the use of radiolabeled antibodies for precise delivery, the challenges in radiopharmaceutical applications, and the promise of antibody engineering to enhance treatment efficacy and safety. It also considers radionuclide selection, conjugation methods, and future innovations in antibody radionuclide conjugates. Abstract Radiotheranostics is a rapidly growing approach in personalized medicine, merging diagnostic imaging and targeted radiotherapy to allow for the precise detection and treatment of diseases, notably cancer. Radiolabeled antibodies have become indispensable tools in the field of cancer theranostics due to their high specificity and affinity for cancer-associated antigens, which allows for accurate targeting with minimal impact on surrounding healthy tissues, enhancing therapeutic efficacy while reducing side effects, immune-modulating ability, and versatility and flexibility in engineering and conjugation. However, there are inherent limitations in using antibodies as a platform for radiopharmaceuticals due to their natural activities within the immune system, large size preventing effective tumor penetration, and relatively long half-life with concerns for prolonged radioactivity exposure. Antibody engineering can solve these challenges while preserving the many advantages of the immunoglobulin framework. In this review, the goal is to give a general overview of antibody engineering and design for tumor radiotheranostics. Particularly, the four ways that antibody engineering is applied to enhance radioimmunoconjugates: pharmacokinetics optimization, site-specific bioconjugation, modulation of Fc interactions, and bispecific construct creation are discussed. The radionuclide choices for designed antibody radionuclide conjugates and conjugation techniques and future directions for antibody radionuclide conjugate innovation and advancement are also discussed.

Gastrin-releasing peptide receptor (GRPR) is a promising target for cancer radiotheranostics combining nuclear imaging with targeted radionuclide therapy. Improving the accumulation of radioligands in...

Radiotheranostics represent a cutting-edge advancement in the management of noncommunicable diseases, integrating diagnostic imaging with targeted rad…

The  Radiotheranostics Market  is evolving rapidly, driven by advancements in technology and increasing demand across diverse industries. De...

The Radiotheranostics Market is evolving rapidly, driven by advancements in technology and increasing demand across diverse industries. Developed by healthcare industry specialists, the Radiotheranost...